Axon Therapies

Axon Therapies is developing a first-in-class neuromodulation therapy targeting the sympathetic nervous system to address the significant unmet need in heart failure with preserved ejection fraction (HFpEF). Its SAVM procedure, performed with the Satera Ablation System, has shown promising 12-month clinical results from the REBALANCE-HF trial, including improved exercise capacity and quality of life. Founded in 2020 and backed by a $32M Series A round, the company is led by a seasoned medtech executive team and supported by investors like Deerfield Management and Action Potential Venture Capital (GSK). Axon represents a paradigm shift from managing symptoms to treating a proposed root cause of heart failure congestion.

Splanchnic Ablation for Volume Management (SAVM): A catheter-based, minimally invasive ablation platform targeting the greater splanchnic nerve to modulate sympathetic nervous system overactivity, a root cause of volume overload in heart failure.

Axon's primary competition comes from pharmaceutical companies developing drugs for HFpEF (e.g., SGLT2 inhibitors, which show modest benefit) and other device companies exploring inter-atrial shunts or pulmonary artery denervation. Axon's SAVM therapy is differentiated by its unique neural target (splanchnic nerve) and proposed mechanism of normalizing volume balance, positioning it as a first-in-class bioelectronic intervention.